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Abstract
Background: Molecular characterization of the FMS-like tyrosine kinase 3 receptor (FLT3) in cytogenetically normal acute
myeloid leukemia (AML) has recently been incorporated into clinical guidelines based on correlations between FLT3 internal
tandem duplications (FLT3-ITD) and decreased disease-free and overall survival. These mutations result in constitutive
activation of FLT3, and FLT3 inhibitors are currently undergoing trials in AML patients selected on FLT3 molecular status.
However, the transient and partial responses observed suggest that FLT3 mutational status alone does not provide
complete information on FLT3 biological activity at the individual patient level. Examination of variation in cellular
responsiveness to signaling modulation may be more informative.
Methodology/Principal Findings: Using single cell network profiling (SCNP), cells were treated with extracellular modulators
and their functional responses were quantified by multiparametric flow cytometry. Intracellular signaling responses were
comparedbetween healthybone marrowmyeloblasts(BMMb)andAMLleukemicblastscharacterizedasFLT3wild type(FLT3-
WT) or FLT3-ITD. Compared to healthy BMMb, FLT3-WT leukemic blasts demonstrated a wide range of signaling responses to
FLT3 ligand (FLT3L), including elevated and sustained PI3K and Ras/Raf/Erk signaling. Distinct signaling and apoptosis profiles
were observed in FLT3-WT and FLT3-ITD AML samples, with more uniform signaling observed in FLT3-ITD AML samples.
Specifically, increased basal p-Stat5 levels, decreased FLT3L induced activation of the PI3K and Ras/Raf/Erk pathways,
decreased IL-27 induced activation of the Jak/Stat pathway, and heightened apoptotic responses to agents inducing DNA
damage were observed in FLT3-ITD AML samples. Preliminary analysis correlating these findings with clinical outcomes
suggests that classification of patient samples based on signaling profiles may more accurately reflect FLT3 signaling
deregulation and provide additional information for disease characterization and management.
Conclusions/Significance: These studies show the feasibility of SCNP to assess modulated intracellular signaling pathways
and characterize the biology of individual AML samples in the context of genetic alterations.
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Introduction
AML is associated with a wide range of genetic alterations,
including mutations in receptor tyrosine kinases (RTKs) that
perturb intracellular signaling networks which play a role in
leukemia pathogenesis and are manifested in the clinical
heterogeneity of the disease. For example, internal tandem
duplications in the juxtamembrane region or tyrosine kinase 1
domains of the FLT3 RTK are reported to result in autonomous,
ligand independent signaling with consequent increases in survival
and proliferation [1–3]. FLT3-ITD mutations are among the most
common somatic mutations in AML occurring in 20–35% of adult
[4–10] and ,5–15% of pediatric [11–13] AML. While the
presence of FLT3-ITD is not predictive of response to conven-
tional induction chemotherapy, the presence of FLT3-ITD has
consistently been shown to confer a poor prognosis with
significantly shorter disease-free and relapse-free survival. Thus,
both the NCCN and European LeukemiaNet guidelines now
recommend testing for FLT3-ITD at diagnosis to guide post-
remission therapeutic selection after induction chemotherapy in
patients with cytogenetically normal (CN) AML [5–8,10–18].
The length of the DNA insertion that constitutes the ITD and the
mutational load or allelic ratio of mutated to wild type (WT) FLT3
receptor vary among patient leukemia samples. Although length of
ITDhasnot been consistently reported to be associated with clinical
outcomes, higher levels of ITD mutational load have been
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this regard, analysis of FLT3-ITD mutational load could provide
more useful information compared to FLT3 receptor mutational
status alone, but it has yet to be included in the current treatment
guidelines. Overall current FLT3 receptor molecular tests provide
no information about the functional consequences of these
mutations on intracellular signaling pathways and do not detect
the presence of other functionally related mutations or alterations
that may cause deregulation of FLT3 receptor pathway activity.
Furthermore the presence of other molecular events such as
nucleophosmin (NPM1), CCAAT/enhancer-binding protein alpha
(CEBP/a), or RUNX1 modifies the prognostic impact of FLT3
receptor mutational status [23–29].
Many studies have provided insight into intracellular signaling
pathways regulated by the FLT3 receptor system [30–37]. Upon
binding FLT3L, the WT FLT3 receptor undergoes dimerization
followed by tyrosine kinase activation, transphosphorylation of the
receptor cytoplasmic domain and recruitment of SH2-domain
containing adaptor proteins which activate downstream signal
transduction pathways such as Ras/Raf/Map Kinase and PI3K. In
contrast, in cell lines expressing FLT3-ITD mutation, these proteins
[in addition to signal transducer and activator of transcription (Stat)
5], are constitutively phosphorylated [34–36,38–40]. Of relevance,
increased basal levels of p-Stat5 AML blasts were shown to be
predictive of the presence of FLT3-ITD mutations in patient
samples [41].
Single cell network profiling (SCNP) using multiparameter flow
cytometry is a distinct proteomic platform for analyzing and
interpreting protein expression and pathway activity under
baseline and modulated conditions. Using viable cells, measure-
ments of endogenous proteins in relevant signaling pathways are
made before and after in vitro exposure to modulators such as
growth factors, cytokines or therapeutic agents known to be
important for myeloid biology and clinical application (Table 1,
Table S1). SCNP interrogates the physiology of signaling pathways
in single cells by measuring network properties not apparent in
resting cells (e.g. failure of a specific pathway to become activated,
hyper/hyposensitivity of the pathway to physiologic stimulators,
altered response kinetics and rewiring of canonical pathways) thus
revealing otherwise unseen functional heterogeneity in apparently
morphologically and molecularly homogeneous disease groups.
When applied to pathways shown to be important in the disease
pathology, mapping of signaling networks by SCNP has potential
applications in diagnostic testing and drug profiling [39,42–46].
Alterations in kinases, phosphatases and transcription factors
can lead to aberrant changes in intracellular protein networks
resulting in increased proliferation and survival, and blocks in
differentiation, and contributing to the pathogenesis of AML. In
this report, using diagnostic non-M3 AML patients, we show that
SCNP characterizes AML signaling pathways (Table 1) and
provides additional information that is not captured by FLT3
receptor mutational status alone. This is the first step in a series of
studies aimed at the development and subsequent validation of
functional signaling readouts in the context of FLT3 receptor
pathway deregulation; this information provides insight into
critical functional dependencies of individual AML on specific
signaling pathways, information which is potentially clinically
relevant and may ultimately be used to inform selection of patients
for treatment with inhibitors of these pathways.
Results
Patient and Sample Characteristics
This study utilized two separate cohorts of patients. The first
sample set (study one) consisted of 34 cryopreserved diagnostic
peripheral blood mononuclear cell (PBMC) samples collected
between September 1998 and September 2007 from AML (non-
M3) patients treated at hospitals affiliated with the University
Health Network (PMH/UHN), University of Toronto. In compar-
ison to the general United States (US) AML population, patients in
this group tended to be younger (74%,60 years), female (62%), of
Asian ancestry (29%), and had primary refractory (NR) leukemia
(74%) (Table 2). Most leukemias were of cytogenetically normal
(CN) intermediate-risk cytogenetics (76%) with half of those
expressing FLT3-ITD. In study one, sample characteristics of
patient age, gender, race and cytogenetic risk were similar in
samples negative (FLT3-WT) and positive (FLT3-ITD) for ITD
mutations (Table 2). One AML sample had a FLT3 receptor
tyrosine kinase domain mutation (TKD). Patient survival curves in
the context of presenceor absence of FLT3 receptor ITD mutations
demonstrated expected trends (Figure S1A) [5–8,10–16].
The second sample set (study two) consisted of 83 cryopreserved
diagnostic bone marrow mononuclear cell (BMMC) samples
collected from AML (non-M3) patients treated at MD Anderson
Cancer Center (MDACC) between September 1999 and Septem-
ber 2006 (Table 2). This sample set was more representative of the
US AML patient population for expected response rates to
induction therapy and clinical characteristics except for gender
(55% female) and age at diagnosis (76%,60 years). Importantly,
FLT3-ITD samples were similar to FLT3-WT samples for patient
age, gender, and clinical response to induction chemotherapy
(Table 2). Poor risk cytogenetics AML was more frequent in
FLT3-WT samples (51%) than in FLT3-ITD samples(31%); FLT3
receptor TKD mutation was present in (2/16) FLT3-ITD and (4/
67) FLT3-WT samples. Survival curves in the context of FLT3-
ITD showed expected trends (Figure S1B) [5–8,10–16].
Ten healthy BMMC taken from male and female volunteers
aged between 24–80 years (mean=66 years) were analyzed as
Table 1. Examples of nodes and pathways analyzed using SCNP.
Relevant Biology Modulator Pathway Readouts
Growth & Stem Cell Factor Responsiveness SCF, FLT3L PI3K, Ras/Raf/Erk p-Akt, p-Erk, p-S6
Interleukin & Cytokine Responsiveness IL-27, G-CSF Jak/Stat p-Stat1, p-Stat3, p-Stat5
DNA Damage & Apoptosis Etoposide, DNA Damage induced Apoptosis p-Chk2, Cleaved PARP
Ara-C/Daunorubicin (Double strand breaks)
Expression of Surface Markers n.a. Drug Transporters & ABCG2, FLT3, C-Kit
Growth Factor receptors
Note: See Table S1 for the complete list of nodes analyzed.
doi:10.1371/journal.pone.0013543.t001
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Donors Are Classified by FLT3-ITD Mutation Status
Study 1 Study 2
FLT3-ITD Status FLT3-ITD Status
Characteristic ITD WT All P-value
2 ITD WT All P-value
2
Age (yr) N 15 19 34 . 16 67 83 .
Mean (Std dev) 47.2 (14.34) 52.9 (13.06) 50.4 (13.73) 0.237 51.6 (11.37) 54.0 (12.35) 53.5 (12.14) 0.48
Median 47.9 52.4 49.1 . 49.7 55.3 55.1 .
Min, Max 20.7, 71.1 31.0, 74.8 20.7, 74.8 . 34.9, 75.7 25.0, 79.0 25.0, 79.0 .
Age Group ,60 yr 12 (80%) 13 (68%) 25 (74%) 0.697 13 (81%) 50 (75%) 63 (76%) 0.75
$60 yr 3 (20%) 6 (32%) 9 (26%) . 3 (19%) 17 (25%) 20 (24%) .
Sex F 9 (60%) 12 (63%) 21 (62%) 1 11 (69%) 35 (52%) 46 (55%) 0.274
M 6 (40%) 7 (37%) 13 (38%) . 5 (31%) 32 (48%) 37 (45%) .
Cytogenetic Groups Favorable 0 (0%) 1 (5%) 1 (3%) 0.311 0 (0%) 7 (10%) 7 (8%) 0.07
Intermediate 13 (87%) 13 (68%) 26 (76%) . 11 (69%) 26 (39%) 37 (45%) .
Unfavorable 0 (0%) 3 (16%) 3 (9%) . 5 (31%) 34 (51%) 39 (47%) .
Not Done 2 (13%) 2 (11%) 4 (12%) . 0 (0%) 0 (0%) 0 (0%) .
Induction Response
1 CR 5 (33%) 4 (21%) 9 (26%) 0.462 11 (69%) 44 (66%) 55 (66%) 1
NR 10 (67%) 15 (79%) 25 (74%) . 5 (31%) 23 (34%) 28 (34%) .
Overall Survival
(weeks)
Median
(95% Conf. Interval)
45.71
(34.47, 56.96)
57.29
(10.11,104.46)
52.14
(35.16, 68.83)
0.040 99.71
(55.78, 143.64)
54.29
(37.49, 71.08)
63.28
(48.49, 78.09)
0.039
CR Duration
(weeks)
Median
(95% Conf. Interval)
47.00
(30.94, 63.05)
62.86
(30.87, 94.85)
47.00
(30.59, 63.41)
0.875 23.14
(216.20, 62.49)
50.00
(29.44, 70.56)
50.00
(31.34, 68.66)
0.006
Race Black 0 (0%) 3 (16%) 3 (9%) . 3 (19%) 3 (4%) 6 (7%) .
White 9 (60%) 11 (58%) 20 (59%) . 7 (44%) 23 (34%) 30 (36%) .
Hispanic 0 (0%) 0 (0%) 0 (0%) . 1 (6%) 4 (6%) 5 (6%) .
Asian 6 (40%) 4 (21%) 10 (29%) 0.242 0 (0%) 1 (1%) 1 (1%) 0.238
Unknown 0 (0%) 1 (5%) 1 (3%) . 5 (31%) 36 (54%) 41 (49%) .
FAB M0 0 (0%) 2 (11%) 2 (6%) 0.234 0 (0%) 1 (1%) 1 (1%) 0.086
M1 1 (7%) 3 (16%) 4 (12%) . 5 (31%) 4 (6%) 9 (11%) .
M2 5 (33%) 1 (5%) 6 (18%) . 6 (38%) 27 (40%) 33 (40%) .
M4 4 (27%) 4 (21%) 8 (24%) . 2 (13%) 19 (28%) 21 (25%) .
M5 1 (7%) 4 (21%) 5 (15%) . 3 (19%) 9 (13%) 12 (14%) .
Unknown 3 (20%) 4 (21%) 7 (21%) . 0 (0%) 3 (4%) 3 (4%) .
M6 0 (0%) 0 (0%) 0 (0%) . 0 (0%) 4 (6%) 4 (5%) .
Mixed lineage 0 (0%) 1 (5%) 1 (3%) . 0 (0%) 0 (0%) 0 (0%) .
Tri-lineage dysplasia 1 (7%) 0 (0%) 1 (3%) . 0 (0%) 0 (0%) 0 (0%) .
FLT3-TKD Negative 15 (100%) 18 (95%) 33 (97%) 0.367 14 (88%) 63 (94%) 77 (93%) 0.365
Positive 0 (0%) 1 (5%) 1 (3%) . 2 (13%) 4 (6%) 6 (7%) .
Secondary AML No 15 (100%) 18 (95%) 33 (97%) 0.367 13 (81%) 46 (69%) 59 (71%) 0.318
Yes 0 (0%) 1 (5%) 1 (3%) . 3 (19%) 21 (31%) 24 (29%) .
Chemotherapy Fludarabine + HDAC 0 (0%) 0 (0%) 0 (0%) . 0 (0%) 12 (18%) 12 (14%) 0.302
IA + Zarnestra 0 (0%) 0 (0%) 0 (0%) . 5 (31%) 21 (31%) 26 (31%) .
IDA + HDAC 0 (0%) 0 (0%) 0 (0%) . 6 (38%) 19 (28%) 25 (30%) .
Other 0 (0%) 0 (0%) 0 (0%) . 5 (31%) 15 (22%) 20 (24%) .
Standard 3 + 7 15 (100%) 19 (100%) 34 (100%) . 0 (0%) 0 (0%) 0 (0%) .
1There are 25 primary refractory patients and 6 failed patients in Study 2.
2P-values were caluclated as follows:
Median survival was estimated from Kaplan-Meier survival curves; the p-value is the log-rank test.
Fisher’s Exact test or the standard Chi-Square test was used to compare donors with FLT3-ITD, FLT3-WT, or Unknown status with respect to categorical variables.
The two-sample ttest was used to compare mean ages of FLT3-ITD and FLT3-WT donors; donors with unknown status were not included in the comparison.
doi:10.1371/journal.pone.0013543.t002
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and study two. Additionally, eight control BMMC samples were
analyzed separately in order to characterize FLT3L induced
signaling in healthy myeloblasts.
Comparison of FLT3- WT Signaling in Healthy and AML
Samples
To analyze modulator-antibody combinations, hereafter de-
fined as signaling nodes, several metrics were developed to
describe pathway activity: Basal (basal, modulator-independent
activity), Fold Change (modulator-induced), and Total (overall
pathway activity) (Figure 1 and Methods). ‘‘Node | metric’’
combinations were used to analyze SCNP data. Study one and two
were conducted sequentially. Reagents and cytometers were
characterized and calibrated respectively, after the first study,
which resulted in some experimental differences between the two
studies preventing the merger of raw data. Therefore, the results
from each study were analyzed independently. Overall trends are
comparable between the studies but absolute values are not. Key
pathways analyzed were Ras/Raf/MAPK, PI3K/Akt, PLCc/
CREB, Jak/Stat, and Apoptosis (Table 1) [47–51].
SCNP was utilized to compare WT FLT3 receptor signaling in
healthy BMMb versus FLT3-WT leukemic blasts (see Methods for
gating hierarchy). As expected based on data from leukemic cell
line experiments, FLT3L activated the MAPK and PI3K
pathways inducing increased levels of p-Akt and p-S6 [30–37].
However, there were kinetic differences for WT FLT3 receptor
signaling in healthy BMMb versus AML blasts. While increases in
p-Erk and p-Akt in response to FLT3L were observed at earlier
time points (Figure 2), activation of these proteins was largely
diminished by 159 in healthy BMMb likely due to regulatory
feedback mechanisms [52]. In contrast, sustained p-Erk and p-Akt
was observed in a number of FLT3-WT AML samples at 159
compared to healthy BMMb (Table 3) and elevated signaling was
evident at earlier timepoints (Figure 2). In healthy myeloid cells,
FLT3L induced a narrow range of signaling with no increases in p-
Stat5 (Table S2A, Table 3). In contrast, in FLT3-WT AML
samples FLT3L induced a wide range of signaling independent of
the level of FLT3 receptor [although samples with the lowest
FLT3 levels demonstrated no FLT3L induced signaling (Table 3,
Figure 3A, 3B, 4A)]. As compared with healthy BMMb, FLT3-
WT samples displayed deregulated FLT3 receptor signaling
ranging from having no induced signaling, to having sustained
levels of p-CREB, p-Akt, p-Erk at 159, earlier induction of p-S6,
and in one case a 2.57 fold increase in p-Stat5, after modulation
with FLT3L (Table 3, Figure 2). In agreement, standard deviations
from measures of FLT3 signaling were higher in FLT3-WT AML
than in healthy BMMb. In addition, the variance in FLT3
Figure 1. Role of each metric in assessing different aspects of signaling biology. Summary schema of all metrics used in the two studies
and the role each has in assessing different aspects of signaling and pathway biology. Median Fluorescence Intensities (MFI) were calculated for
leukemic blast cells in each condition and used to compute metrics for Relative Expression of surface expression markers and Basal, Fold and Total
measurements of signaling as described in Results. Definitions of metrics used to analyze surface marker expression, signaling data, and apoptosis
readouts are shown (i.e. Basal = log2(UnmodulatedMFI/AutofluorescenceMFI).
doi:10.1371/journal.pone.0013543.g001
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Levene’s test) between the FLT3-WT AML and healthy BMMb
samples (Table S2A) [53]. Furthermore, although individual
healthy and AML samples displayed uniform FLT3 receptor
staining, FLT3L responsiveness and induction of p-S6 was only
observed in a fraction of cells (Figure 3B).
Signaling and Apoptosis Nodes Stratify FLT3-WT and
FLT3-ITD AML Samples
To assess signaling differences between FLT3-WT and FLT3-
ITD AML samples, we used SCNP to measure the activities of
pathways that regulate hematopoietic cell proliferation and
differentiation, drug transport, apoptosis, and DNA damage
response/apoptosis (Table 1, Table S1).
Univariate analysis, unadjusted for multiple testing, was
performed sequentially and independently on the two study
cohorts to identify signaling nodes commonly associated with
FLT3 receptor mutational status (Table 4). Seventy seven of 304
and 48 of 201 node/metrics tested in studies one and two
respectively distinguished FLT3-ITD from FLT3-WT AML
patient samples with an AUC of ROC $0.6 and p#0.05 (Tables
S3, S4). Analysis of false discovery rate for both studies showed this
frequency to be significantly greater than the number of signaling
nodes that would be expected to be significantly different between
the two groups just by chance (p = 0.0009 study one and
p,0.0001 study two respectively) (Figure S2). Stratifying nodes
that distinguished FLT3-ITD from FLT3-WT samples in both
studies represented distinct biological networks including Jak/Stat,
PI3K and apoptosis pathway readouts (Figures 4, 5, 6, Table 4).
FLT3 Receptor Levels and Signaling Activity in FLT3-WT
and FLT3-ITD Samples
Although FLT3-ITD and FLT3-WT samples expressed similar
levels of the FLT3 receptor, FLT3L induced distinct signaling
responses in the two types of sample sets (Figures 4A, B). In
addition, basal levels of p-Erk, p-Akt, and p-S6 did not differ
significantly between FLT3-ITD and FLT3-WT blasts (Figure
S3A). After modulation with FLT3L, FLT3-ITD samples showed
lower levels of induced PI3K and MAPK pathway activation
compared to FLT3-WT samples (Figure 4, Tables S3, S4, Figure
S4). This was particularly evident for FLT3L induction of p-S6
(Figure 4A) which, in both studies, by univariate analysis,
discriminated between FLT3-ITD and FLT3-WT samples
(FLT3LRp-S6 | Fold, AUC of ROC 0.72 and 0.68 for study
Figure 2. FLT3L Induced Signaling Kinetics in Healthy Bone Marrow Myeloblasts (BMMb) and FLT3-WT AML blasts. Shown are kinetics
of FLT3L induced p-Akt (upper) and p-S6 (lower panels) in FLT3-WT AML (left) and healthy control BMMb from Study 2 (center) and additional healthy
BMMb samples from a separate cohort (n=8) (right). While BMMb displayed fairly uniform kinetics of FLT3L induced p-Akt and p-S6, FLT3-WT AML
demonstrated a range of kinetic responses including elevated and sustained p-Akt and a rapid, heightened induction of p-S6 compared to healthy
BMMb. Additional BMMb were analyzed from a separate study (right panel) to increase the number of healthy controls analyzed. Note: absolute
values are not comparable between studies due to different experimental configurations.
doi:10.1371/journal.pone.0013543.g002
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Stat5 levels was observed in FLT3-ITD and FLT3-WT samples,
with higher levels observed in FLT3-ITD samples (Figure 4B).
Notably, while FLT3L stimulation did not further increase p-Stat5
in FLT3-ITD samples, FLT3L was able to increase p-Stat5 in one
FLT3-WT (and NPM1-WT) sample (Figure 4B), a response not
observed in healthy myeloid cells, suggesting deregulated FLT3
receptor signaling both in the presence and absence of known
FLT3 receptor mutational alterations. Notably, for most FLT3L
inducible readouts a wider range of responses was observed in
FLT3-WT samples while FLT3-ITD samples behaved more
uniformly (Figure 4, Figure S4). In agreement, FLT3-WT AML
demonstrated higher standard deviations of FLT3 induced p-S6
than FLT3-ITD AML, and the difference in variance between the
groups was statistically significant (p-value,0.001, Levene’s test)
(Table S2A) [53].
Distinct Jak/Stat Signaling in FLT3-WT and FLT3-ITD
Samples
While a wide range of IL-27 Rp-Stat responses were observed
in the FLT3-WT samples, FLT3-ITD samples behaved much
more uniformly and displayed minimal responsiveness to IL-27
stimulation. A comparison of basal p-Stats levels for FLT3-ITD
versus FLT3-WT showed that p-Stat1, p-Stat3, and p-Stat5 were
increased in FLT3-ITD samples in study one but not in study two
(Figure S3B). Furthermore, IL-27 mediated Jak/Stat pathway
activity was lower in FLT3-ITD samples compared to FLT3-WT
samples with significantly lower induction of p-Stat3 (p#0.029)
and p-Stat5 (p#0.038) in both studies (Figure 5A). The IL-27 R
p-Stat 3 | Fold signaling node in univariate analysis stratified
FLT3-ITD positive from FLT3-ITD negative samples (AUC 0.69
study one and AUC 0.73 study two respectively) (Table S3, S4).
Distinct Apoptosis Responses seen in FLT3-WT and FLT3-
ITD Samples
In order to determine the integrity of the DNA damage
response (DDR) and apoptotic machinery, the ability of etoposide
to induce DNA damage (increased p-Chk2 levels) and apoptosis
(increased cleaved PARP levels), was measured in leukemic blasts.
FLT3-ITD samples were more sensitive to in vitro apoptosis than
FLT3-WT samples (etoposide R c-PARP| Total AUC 0.82 study
one and AUC 0.73 study two, respectively) (Figure 5B, Tables S3,
S4). Similar results were observed in both studies using other
mechanistically distinct apoptosis-inducing agents such as staur-
osporine, a pan kinase inhibitor, and in study two, Ara-C/
Daunorubicin (Tables S3, S4)
Correlation between Stratifying Nodes
Although the signaling nodes were analyzed independently in
the primary analysis, several of the top-ranking nodes stratifying
FLT3-ITD from FLT3-WT AML samples were correlated with
each other. Pearson correlation coefficients computed for all
signaling nodes with a p#0.05 from study one (Table S5) showed
(as it would be expected) correlation between nodes measuring
signaling events in the same pathway. For example, the following
node/metrics: IL-27Rp-Stat3 | Fold and IL-27Rp-Stat5 | Fold
(R = 0.81) or ThapsigarginRp-CREB | Fold and PMAR
p-CREB | Fold (R = 0.87), suggest common signaling pathways
between the nodes in these pairs. By contrast, poor correlations
were observed between nodes measuring signaling events in
different pathways (such as ThapsigarginRp-CREB | Fold and
IL-27Rp-Stat5 | Fold (R=0.04), suggesting that these nodes are
measuring distinct signaling pathways and might be combined to
produce a multivariate model for prediction of FLT3 receptor
mutational status with higher predictive value (Figure 7).
Association between Multiple Signaling Nodes and FLT3-
ITD Status –Multivariate Analysis using Linear Regression
To determine if different signaling nodes in combination could
provide superior stratification of FLT3-ITD and FLT3-WT AML
samples, all possible pairs of the 80 signaling nodes with AUC of
the ROC §0.7 or lowest p#0.05 from study 1 (Table S3) were
evaluated for their ability to improve stratification of the FLT3
receptor mutational status (Table S6). Given the limited size of this
data set, this modeling exercise was performed to explore potential
Table 3. Summary table comparing FLT3 Receptor and FLT3L induced signaling between normal BM Myeloblasts (BMMb) and
FLT3-WT AML.
Study 1 Study 2
Healthy
BMMb FLT3-WT AML
Healthy
BMMb FLT3-WT AML
Node | Metric: Ave Ave Min Max Ave Ave Min Max
Surface Markers:
FLT3 Receptor | Relative Expression 2.30 1.97 0.79 4.33 1.20 1.27 0.94 2.04
FLT3L induced signaling:*
FLT3L R p-S6 0.51 0.96 20.22 2.91 0.62 1.03 20.47 3.54
FLT3L R p-Akt 0.50 0.63 20.13 2.31 0.43 0.50 20.47 1.66
FLT3L R p-Erk 0.19 0.33 20.18 0.98 0.41 0.25 20.27 0.95
FLT3L R p-CREB 20.11 0.37 20.20 1.29 0.18 0.12 20.17 0.40
FLT3L R p-Stat5 20.06 0.08 20.47 2.57 0.41 0.35 20.01 0.55
FLT3L R p-PLCc2 20.21 20.11 20.53 0.21 0.01 0.04 20.04 0.09
*Signaling assesed at 159.
Note: Mean values are not directly comparable between Study 1 and Study 2 due to experimental configuration and methodological improvements between studies.
No statistics were applied for the Healthy BMMb comparison within Study1 or Study2 alone due to the low number of healthy donors.
See Table S2A for a statistical analysis of varaince for FLT3L induced signaling in FLT3-WT AML and Healthy BMMb samples.
doi:10.1371/journal.pone.0013543.t003
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of future studies. Of note, all combinations that had an AUC
greater than the best single node/metric within the combination
were assessed (please see Materials and Methods). The AUC for
the models ranged from 0.89 to 0.99 (Table S6). As expected, the
probability of two nodes to complement one another was higher if
the nodes participated in different signal transduction pathways:
e.g. combining the nodes p-Stat5 | Basal (AUC=0.85) and
FLT3LRp-S6 | Total (AUC=0.80), (R = 20.12), yields an
improved AUC of 0.97 (Figure 7A, 7B, 7C).
FLT3L and IL-27 Induced Signaling in FLT3-ITD, NPM1
Molecular Subgroups
To understand how FLT3 receptor and NPM1 mutational
status relate to intracellular biological pathways in diagnostic
AML samples, we assessed IL-27 induced Jak/Stat signaling and
FLT3L induced PI3K and Raf/Ras/MAPK signaling responses
in FLT3 receptor and NPM1 molecular defined subgroups.
NPM1 mutational status was available for all patients in study
one but only for a subset in study two; hence the interpretation of
the results of these analysis are limited by the small number of
s a m p l e si ne a c hs u b s e t .F o ra l lnodes analyzed, the FLT3-WT/
NPM-WT subgroup demonstrated t h em o s tv a r i a b l es i g n a l i n g
responses and often contained samples with the most elevated
signaling (Figure S5). In contrast, within FLT3-ITD/NPM1
mutated patients, IL-27-induced and FLT3L-induced signaling
appeared more uniform and generally lower compared to FLT3-
WT/NPM-WT samples. FLT3-WT/NPM1-WT samples dem-
onstrated the highest variance among FLT3 NPM1 subgroups
for IL-27 and FLT3L signaling and demonstrated significantly
higher variance compared to both FLT3-ITD subgroups (Table
S2B). Of note, the largest differences in variance were observed
between FLT3-WT/NPM-WT and FLT3-ITD/NPM-Mutated
samples (Table S2B).
Clinical Implications of These Studies
To assess if functional intracellular pathways characterization
using SCNP may stratify (beyond molecular characterization)
AML for clinical outcomes, the signaling profiles of samples with
clinical outcomes not predicted by molecular findings (here called
‘‘outliers’’) were analyzed.
Signaling profiles were assessed in samples from two groups of
Cytogenetically Normal (CN) AML patients, each representing a
clinically extreme example of an ‘‘outlier’’ (based on the molecular
characterization): 1) FLT3-WT AML who experienced disease
relapse within three months after initial remission and 2) FLT3-
ITD AML in complete continuous disease remission for two or
more years. In the first study there were no patient samples that
met these two criteria. In the second study there were two FLT3-
WT and two FLT3-ITD samples respectively (Table 5). Clinical
characteristics of CN AML samples used for this subset analysis
from both studies are presented in Table S7.
The wide range of signaling responses observed in FLT3-WT
AML samples made identification of signaling outliers in this
subgroup challenging. Examination of the signaling profiles in the
two FLT3-WT samples with relapse ,3 months (MD3–19 and
MD3–37) showed low p-S6 and p-Erk in response to FLT3L,
similar to induced signaling observed in FLT3-ITD samples
(Figure 8A). In addition, MD3–19 showed minimal IL-27
mediated Stat phosphorylation, similar to FLT3-ITD samples
(Figure 8B), suggesting that these FLT3-WT samples from patients
with rapid disease relapse might share similar biology with FLT3-
ITD samples in certain pathways. In contrast, identification of
FLT3-ITD signaling outliers was aided by the narrow range of
signaling responses observed in this sample set. In the CN FLT3-
ITD sample group, two patients remained in complete continuous
remission for two or more years, one (MD2–22) having been
treated with chemotherapy alone and the other (MD3–22) treated
with an allogeneic stem cell transplant (as per NCCN guidelines).
Since MD3–22 received high intensity post-remission therapy we
focused on signaling associated with sample MD2–22 obtained
from a patient who received high dose cytarabine similar to what is
recommended for ‘‘low risk’’ cytogenetic leukemia. We found that
the FLT3-ITD MD2–22 sample signaling profile was closer to
FLT3-WT as illustrated by the first two principal components of
PCA Analysis using FLT3 stratifying nodes (Figure 8C). This
observation was further reinforced by the number of nodes (16) for
which MD2–22 was an outlier among the FLT3-ITD group (i.e.
outside of 1.5 times the inter-quartile from the median for FLT3-
ITD as shown in Table S8). These nodes included those from the
Jak/Stat pathway PI3K and MAPK pathways (Figure 5A). A
following molecular analysis of this sample indicated the presence
of an NPM1 gene mutation although this information was not
available at the time of post-remission treatment.
We next correlated SCNP signaling and apoptosis nodes with
remission duration in AML samples in the context of FLT3
molecular status. This study was limited to FLT3-WT AML
samples due to insufficient FLT3-ITD samples with CR duration
greater than two years. Within FLT3-WT AML samples, we
found that higher measures of induced apoptosis (i.e. Ara-C/
DaunoRC-PARP | Fold) were associated with CR duration
greater than two years (AUCROC: 0.92) (Figure S6).
Discussion
While genetic and molecular heterogeneity may ultimately
underlie the different responses to therapy observed among
patients with AML, there appears to be a finite number of
intracellular signaling pathways through which these differences
are expressed. These pathways (which include PI3K/Akt, Ras/
Raf/MAPK, and Jak/Stat) play important roles in proliferation,
survival, cell cycle progression, and differentiation in both normal
and leukemic hematopoietic cells [54].
The present studies illustrate the value of using SCNP to
characterize the biologic complexity of AML at the signaling
Figure 3. Wider range of FLT3 receptor levels and responsiveness observed in FLT3-WT AML versus healthy BMMb. A) Comparison of
FLT3 receptor levels and FLT3L induced signaling (FLT3LRp-S6 |Fold) in FLT3-WT AML samples and healthy BMMb from Study 1 (top panel) and
Study 2 (bottom panel). The two distinct healthy BMMb in each study are illustrated by triangle and diamond symbols. Left, Box and whisker plots of
FLT3 receptor levels, center: Box and whisker plots of FLT3L induced p-S6, right scatter plot of FLT3 receptor levels and FLT3L induced p-S6. Note: In
Box and whisker plots, boxes contain 50% of the sample data with the median values indicated with a horizontal bar. Whiskers contain 1.56the
interquartile range and outliers past this range are shown as individual points. Absolute values are not comparable between studies due to
experimental differences in antibody stain time and temperature and choice of a-FLT3 antibody. B) Examples of Healthy BMMb and FLT3-WT AML
FLT3 Receptor levels and signaling: Top panel: histograms of FLT3 receptor (black) vs. control antibody (grey); Bottom panel: histograms of basal
(grey) or FLT3L induced (black) p-S6. The p-S6 positive FLT3L responsive subpopulations are designated with asterisks. Examples of FLT3-WT AML
samples with high FLT3 Receptor levels and low FLT3 Receptor levels are shown.
doi:10.1371/journal.pone.0013543.g003
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to AML using a limited panel of nodes [39], this study describes
the high-throughput application of the technology, using a
standardized 96-well format, examining a broader panel of nodes
(including multiple previously unexamined biological pathways in
the context of FLT3-ITD status) in a larger numbers of AML
patients and in independently assayed sample sets. Results from
this study show the existence of significant differences in
modulated signaling networks between healthy bone marrow
myeloblasts and leukemic AML blasts and, in the latter group,
between FLT3 receptor molecularly defined subsets.
While much has been learned from experiments in leukemic cell
lines there is little published data on WT FLT3 receptor signaling
in healthy bone marrow myeloblasts (BMMb) and primary
leukemic blasts [2,55]. The broad functional assessment of
biologically relevant signaling pathways in AML blasts and
BMMb conducted in this study shows a spectrum of signal
transduction deregulation not previously described in primary
Figure 4. Variable and increased range FLT3L induced PI3K and Raf/Ras/Erk pathways in FLT3-WT versus FLT3-ITD AML. A)
Comparison of FLT3 receptor levels and FLT3L induced signaling (FLT3L R p-S6 |Fold) in FLT3-WT (pluses) and FLT3-ITD (squares) AML samples from
Study 1 (top panel) and Study 2 (bottom panel). Left, FLT3 receptor levels, center: FLT3L induced p-S6, right combination plot of FLT3 receptor levels
and FLT3L induced p-S6. Note: Absolute values are not comparable between studies. B) Example of p-Stat5 | Basal and FLT3L R p-Stat5 | Fold levels
from Study 1 demonstrates a FLT3L R p-Stat5 response from a FLT3-WT NPM1-WT sample (UHN_0521).
doi:10.1371/journal.pone.0013543.g004
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| Fold signaling responses for FLT3-WT and FLT3-ITD samples from Study 1 (top row) and Study 2 (bottom row) were greater and more variable in
FLT3-WT compared to FLT3-ITD AML samples. B) Etoposide R cleaved PARP | Total levels for FLT3-WT and FLT3-ITD samples from Study 1 (top row)
and Study 2 (bottom row) demonstrate increased in vitro apoptosis after continuous etoposide treatment in FLT3-ITD vs. FLT3-WT samples. Note:
Absolute values are not comparable between studies.
doi:10.1371/journal.pone.0013543.g005
Table 4. Summary table of common stratifying pathways between FLT3-WT and FLT3-ITD signaling in AML samples in both
studies.
Study 1 Study 2
Node | Metric:
FLT3-WT
AML
FLT3-ITD
AML AUCROC
t-test
P
Wilcox.
P
Mean Value of
WT/ITD AUCROC
t-test
P
Wilcox.
P
Mean Value of
WT/ITD
PI3K/S6 induced Signaling:
FLT3L R p-S6 | Fold q 0.72 0.014 0.038 0.96 / 0.30 0.68 0.028 0.036 1.03 / 0.43
FLT3L R p-S6 | Total q 0.80 0.003 0.003 1.46 / 0.45 0.65 0.035 0.119 4.09 / 3.27
Jak/Stat Signaling:
IL-27 R p-Stat3 | Fold q 0.69 0.029 0.076 0.64 / 0.23 0.73 0.002 0.022 0.37 / 0.04
IL-27 R p-Stat5 | Fold q 0.70 0.038 0.059 0.21 / 0.00 0.63 0.024 0.207 0.15 / 20.02
Functional Apoptosis Response:
Etoposide R c-PARP | Total q 0.82 0.001 0.003 1.06 / 2.79 0.73 0.005 0.013 2.81 / 4.45
q = higher signaling response in indicated molecular group.
For detailed information for each Study see Tables S3 and S4.
Note: Mean values are not directly comparable between Study 1 and Study 2 due to experimental configuration and methodological improvements between studies.
doi:10.1371/journal.pone.0013543.t004
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analysis comparing basal and modulator-induced activity of
multiple distinct pathways such as Jak/Stat, PI3-kinase/Akt/S6
and the Ras/Raf/Erk/S6, phosphatase/reactive oxygen species,
and DDR/apoptosis pathways in the context of FLT3 status. To
our knowledge this is also the first study that measured FLT3
receptor expression levels in conjunction with signaling profiles in
primary leukemia samples. Although FLT3 receptor levels were
similar between the FTL3-WT and FLT3-ITD AML groups,
FLT3-ITD expressing samples displayed attenuated responses to
FLT3L, as measured by induced levels of p-S6, p-Erk, p-Akt and
p-CREB versus their FLT3-WT counterparts (Tables 4, S3, S4
and Figure S4). FLT3-ITD expressing cell lines have been
reported to have ligand independent signaling with increased
levels of basal p-Erk and p-Akt [38]. However, in the primary
leukemic blasts tested in this study, basal levels of p-Erk, p-Akt,
and p-S6 did not differ significantly between FLT3-ITD and
FLT3-WT blasts (Figure S3A). Of note, most studies examining
FLT3-ITD in cell lines, have introduced the FLT3-ITD mutation
into an already transformed cell with existing mutations and
alterations. Overall these data suggest the greater dependence of
FLT3L inducibility of these signaling networks in FLT3-WT AML
and demonstrate FLT3L-independence in FLT3-ITD samples.
Canonical Stat pathways, activated by cytokines, regulate an
array of cellular functions ranging from survival and apoptosis to
proliferation and differentiation [56]. In this study there was no basal
or FLT3L-induced activation of p-Stat5 in healthy marrow
myeloblasts while AML marrow blasts showed a wide range of basal
p-Stat5 expression even in the absence of FLT3-ITD. Prior studies
have shown that basal p-Stat5 levels are constitutively high in cell lines
that have been transfected with FLT3-ITD genes [32–36,38,57] and
recentlyincreased expression ofp-Stat5 in AML blasts wasfound to be
highly predictive of the presence of FLT3-ITD mutations [41].
Consistent with these studies we found FLT3-ITD samples expressed
increased basal levels of p-Stat1, p-Stat3 and p-Stat5 compared to
FLT3-WT samples in study one and in both studies FLT3-ITD AML
samples displayed a uniformly limited range in basal p-Stat5 levels
compared to FLT3-WT samples. Additionally, in contrast to healthy
bone marrow myeloblasts, FLT3L induced p-Stat5 in some FLT3-
WT samples, demonstrating deregulated FLT3 receptor signaling
even in the absence of FLT3 mutational alterations.
This study is also the first to show different signaling responses
between FLT3-WT and FLT3-ITD in AML samples for IL-27
induced Jak/Stat pathway activity. Most studies characterizing the
biology of IL-27 have been performed on lymphocytes where this
cytokine plays a major role in immune regulation. However, the
IL-27 receptor is present on other cell types, including those of the
myeloid lineage, where its activation has been shown to enhance
proliferation and differentiation of mouse and human hematopoi-
etic stem/progenitor cells [50,58]. In study one, increased levels of
basal p-Stat1 and p-Stat5 were observed for FLT3-ITD compared
to FLT3-WT samples. Our data suggest these FLT3-ITD samples
are less responsive to IL-27 mediated Stat signaling, likely because
they already display elevated Stat pathway activity. This cytokine
independence could contribute to the poor clinical outcome
observed within FLT3-ITD patients.
Finally, analysis of the apoptosis pathway showed that FLT3-
ITD samples were more sensitive in vitro to apoptosis inducing
agents than FLT3-WT samples. Aside from differences in cell
source (primary leukemia blasts versus cell lines) the continuous
exposure of cells to DNA damaging drugs may account for the
difference between our data and published literature, where the
Figure 6. Overview of pathway differences observed between FLT3-ITD and FLT3-WT AML samples across the two studies. Illustration
of pathway differences between FLT3-ITD and FLT3-WT samples. Red coloring of readouts and bold lines indicate increased pathway activity. White
coloringandnon-boldlinesindicatedecreasedpathway activity.Dottedline fromFLT3Ltop-Stat5 inFLT3-WT samplesindicatesconnectivityina subset
of patients. Red ‘‘X’’ indicates DNA Damage. Faded modulators (FLT3L, IL-27) in FLT3-ITD indicate decreased modulator induced signaling.
doi:10.1371/journal.pone.0013543.g006
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resistance to DNA damage induced apoptosis [36,38]. Recent
studies suggest that FLT3-ITD AML samples are more sensitive to
long term drug exposure due to deficient S-phase checkpoints as
compared to FLT3-WT samples [59]. Future studies that examine
longitudinal samples pre- and post-therapy could be informative in
defining the basis of the secondary chemo-resistance characteristic
of FLT3-ITD samples. In addition, while these results may seem
somewhat counterintuitive to the clinical findings that patients
with FLT3 ITD leukemia experience worse overall survival and
shorter disease-free remission, to date the presence of FLT3-ITD
has not been associated with response to induction therapy [17].
Figure 7. Correlations and multivariable analysis of common nodes which stratify FLT3-WT and FLT3-ITD AML samples in Study 1.
A) Correlation (R) Values between FLT3-WT vs. FLT3-ITD stratifying nodes demonstrate correlated nodes/pathways (IL-27Rp-Stat3 | Fold, IL-27 R
p-Stat5, | Fold: R=.81) and non-correlated nodes/pathways (IL-27 R p-Stat5, | Fold, FLT3L R p-S6 | Total: R=.19) suggesting that distinct pathways
may provide independent information in characterizing the biology of FLT3-ITD and FLT3-WT AML samples. An R value of 0 indicates no correlation,
positive R values (0–1) indicate positive correlation and negative R values (21 to 0) indicate negative correlation. Correlations based on 25 donors
with data for all nodes. See Table S5 for additional nodes. B) Multivariate analysis showing combining pairs of nodes can improve stratification over
single nodes for stratifying FLT3-ITD and FLT3-WT samples. Shown is a combination plot of p-Stat5 | Basal, FLT3L R p-S6 | Total with FLT3-ITD
samples. The dotted line shows how stratification between FLT3-WT (pluses) and FLT3-ITD (squares) is improved using combinations of independent
stratifying nodes. C) AUCROC values for individual nodes (p-Stat5 | Basal, FLT3L R p-S6 | Total), and the nodes in combination.
doi:10.1371/journal.pone.0013543.g007
Table 5. Identification of cytogenetically normal clinical
outliers.
FLT3 Status Relapse ,3 Months Remission .2 Years
Study 1: ITD 00
WT 00
Study 2: ITD 2 2
WT 2 9
doi:10.1371/journal.pone.0013543.t005
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heterogeneity in AML and has potential as a platform for
understanding leukemia pathway dependency in the individual
patient, information that could be valuable for the selection of
therapeutic strategies in the era of personalized medicine. This
method promises to reduce the complicated genetic picture that is
emerging for AML to the functional status of a few distinct
signaling pathways.
However, whether the SCNP methodology will provide
clinically useful and actionable information beyond existing
molecular markers remains to be proven (in this study no data
were available on additional molecular alterations).
Lastly, multiple therapeutics that target FLT3 receptor (e.g.,
CEP701, PKC412, AB220) are in development for the treatment
of AML. To date, the characterization of AML based on the
mutational status of the FLT3 gene has shown not to be very
informative in predicting the activity of any of these FLT3
receptor inhibitors and their effects on signaling transduction
remains unknown. In this regard, SCNP could be tested as a tool
to identify AML patients who could benefit from administration of
such inhibitors alone or in combinations with other standard
agents and/or targeted inhibitors. Further studies in the context of
clinical trials are warranted.
Materials and Methods
Ethics Statement
In accordance with the Declaration of Helsinki, all patients
provided written informed consent for the collection and use of
their samples for research purposes. All studies were approved by
Figure 8. Signaling profiles of ‘‘clinical outliers’’. A) Scatter plot of FLT3L R p-Erk | Fold (X-axis) and FLT3L R p-S6 | Fold (Y-axis) for FLT3-ITD
samples (left, squares) and FLT3-WT samples (right, pluses). Samples MD3–19 and MD3–37, FLT3-WT samples with Rapid Relapse, display low FLT3L
induced signaling, similar to FLT3-ITD samples, and are shown. B) Scatter plot of IL-27 R p-Stat3 | Fold (X-axis) and IL-27 R p-Stat1 | Fold (Y-axis) for
FLT3-ITD samples (left, squares) and FLT3-WT samples (right, pluses). Sample MD3–19 (FLT3-WT rapid relapse sample) displays low IL-27 induced
signaling, similar to FLT3-ITD samples, and is shown. Also indicated is FLT3-ITD outlier MD2–22 which demonstrates higher IL-27 induced signaling
similar to FLT3-WT samples. C) Principal Component Analysis of stratifying nodes with outliers illustrates that while most FLT3-ITD samples cluster
together (squares), FLT3-WT samples (pluses) are more heterogeneous and sample MD2–22 (circled) signals distinctly from other FLT3-ITD samples.
This indicates that clinical outlier MD2–22, a FLT3-ITD sample with remission .2 years, signals in many nodes like a FLT3-WT sample.
doi:10.1371/journal.pone.0013543.g008
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Research Ethics Board (study one), M.D. Anderson Cancer Center
Institutional Review Board (study two), and Independent Review
Consulting, Inc. (Healthy BMMC Study). Clinical data were de-
identified in compliance with Health Insurance Portability and
Accountability Act regulations.
Patient Samples
Sample inclusion criteria included diagnosis of AML, French-
American-British classification as M0 through M7 AML (exclud-
ing M3), collection prior to the initiation of induction chemother-
apy, molecular determination of the presence or absence of FLT3-
ITD, post-thaw cell viability of .50% and .500 cells in the
leukemic cell population (defined below). All samples underwent
fractionation over Ficoll-Hypaque prior to cryopreservation with
fetal calf serum and 10% dimethyl sulfoxide and storage in liquid
nitrogen.
The first sample set consisted of 34 cryopreserved peripheral blood
mononuclear cell (PBMC) samples collected from AML (non-M3)
patients treated at hospitals affiliated with the PMH/UHN,
University of Toronto, between September 1998 and September
2007. Induction chemotherapy consisted of one cycle of standard
cytarabine-based induction therapy (daunorubicin 60 mg/m
2 6 3
days,cytarabine 100–200 mg/m
2continuous infusion67d a y s) .T h e
second sample set consisted of 83 cryopreserved BMMC samples
collected from AML (non-M3) patients treated at MDACC between
September 1999 and September 2006. Induction chemotherapy
consisted of one or two cycles of cytarabine (200 mg/m
2 to 3 g/m
2)
in combination with an anthracycline (daunorubicin or idarubicin) or
an additional anti-metabolite (e.g., fludarabine or troxacitabine), and
sometimes an experimental agent. However, due to differences in cell
number post-thaw in this study, the number of patients for whichdata
was available for a given node/metric varied between 83 and 9.
Standard clinical and laboratory criteria were used for defining
complete response (CR) in both studies [60].
A total of ten healthy BMMC were analyzed in these studies.
Two healthy BMMC controls (obtained from All Cells) as well as 2
cell lines were used in studies one and two as assay controls.
Additionally, eight healthy BMMC controls were obtained from
Williamson Medical Center and assayed in a separate study.
Analysis of FLT3 Receptor Mutational Status
In study one, an aliquot of cells were taken from each sample
and DNA and RNA were isolated using TRIzol Reagent
(Invitrogen) as described by the manufacturer. In study two,
FLT3 receptor gene mutational status was assessed at MDACC.
For the analysis of internal tandem duplication of the FLT3
receptor gene, PCR was performed on 500 ng genomic DNA
using published primers 11F and 12R as described to identify ITD
insertions in the JM and TK1 domains [14] using AmpliTaq Gold
DNA polymerase (Applied Biosystems) and 3% agarose gels. For
samples with no available genomic DNA, the PCR assay was
performed with 100 ng of cDNA prepared using the High
Capacity RNA-to cDNA kit (Applied Biosystems).
For the screening of FLT3 receptor D835 mutation by RFLP
analysis PCR was performed on 500 ng genomic DNA using
published primers 17F and 17R as described [61]. 5 ml of PCR
product was digested with 5 U of EcoRV for 1.5 hours at 37uC
then analyzed by gel electrophoresis. For samples with no
available genomic DNA, the D835 PCR assay was performed
using 100 ng of cDNA and reverse primer FLT3-D835R2, 59-
TTGCCCCTGACAACATAGTTGGA-39, designed for a cDNA
template.
Analysis of NPM1 Mutational Status
In study one, Real-time quantitative PCR assays for NPM1
mutations A and B: RQ-PCR were performed on 100 ng cDNA
using published primers and Taqman probe cNPM-F, c. Probe,
cNPM mut.A-R, cNPM mut.B-R as described [62] except 40
PCR cycles were used. In study two, standard PCR assays were
performed for detection of NPM1 mutations with forward primer
59-[6-FAM]-GATGTCTATGAAGTGTTGTGGTTC-39 and re-
verse primer 59-GTTTCTAAGGACAGCCAGATATC.
SCNP Assay
The analysis included response to chemokines, cytokines,
growth factors such as: SCF and FLT3L- mediated PI3K/Akt
and MAPK pathway activation (important for maintaining the
hematopoietic stem cell pool [47,48]; G-CSF- mediated Jak/Stat
pathway activation (important for neutrophilic differentiation of
hematopoietic progenitor cells [49]; and interleukin (IL)-6 family
members, including IL-27, mediated Jak/Stat pathway activation
(important in regulating proliferation and differentiation of
hematopoietic stem cells [50]. Drug transporter expression levels,
known to be associated with adverse prognosis in AML, [63,64]
and surface myeloid growth factor receptors levels such as c-Kit
and FLT3 receptors, were also measured. DNA Damage
Response (DDR) and apoptosis pathways were measured using
p-Chk2 and cleaved PARP after in vitro exposure of AML samples
to etoposide, Ara-C/daunorubicin or staurosporine.
SCNP assays were performed as described previously [39].
Cryopreserved samples were thawed at 37uC, washed, and
centrifuged in PBS, 10% FBS, and 2 mM EDTA. The cells were
re-suspended, filtered to remove debris, and washed in RPMI cell
culture media 1% FBS, before staining with Aqua Viability Dye to
distinguish non-viable cells. The cells were re-suspended in RPMI,
1% FBS, aliquoted to 100,000 cells/condition, and rested for 1–
2 hours at 37uC. For apoptosis assays, cells were incubated for 6h
with Staurosporine or 24 hours with cytotoxic drugs (e.g., etoposide
or Ara-C and daunorubicin) and re-stained with Aqua Viability
Dye. For all other assays, cells were incubated with modulators
(Table S1) at 37uC for 3–15 minutes. After exposure to modulators,
cells were fixed with 1.6% paraformaldehyde (final concentration)
for 10 minutes at 37uC, pelleted and permeabilized with 100% ice-
cold methanol, and stored at 280uC. Subsequently, cells were
washed with FACS buffer (PBS, 0.5% BSA, 0.05% NaN3), pelleted,
and stained with cocktails of fluorochrome –conjugated antibodies
(Table S9). These cocktails included antibodies against 2 to 5
phenotypic markers for cell population gating (e.g., CD45, CD33),
up to 3 antibodies against intracellular signaling molecules, or
against surface markers for an 8-color flow cytometry assay. Isotype
controls or phosphopeptide blocking experiments were performed
to characterize each phospho-antibody.
Flow Cytometry Data Acquisition and Analysis
Flow cytometry data was acquired on an LSR II and/or
CANTO II flow cytometer using the FACS DIVA software (BD
Biosciences, San Jose, CA). All flow cytometry data were analyzed
with FlowJo (TreeStar Software, Ashland, OR) or WinList (Verity
House Software, Topsham, ME). Dead cells and debris were
excluded by forward scatter, side scatter, and Amine Aqua
Viability Dye measurement. Leukemic cells were identified as cells
that fit the CD45 and CD33 versus right-angle light-scatter
characteristics consistent with myeloid leukemia blasts and that
lacked the characteristics of mature lymphocytes (CD45
+, CD33
2)
(Figure S7) [65] Healthy bone marrow myeloblasts (BMMb) were
identified from bone marrow mononuclear cell (BMMC) samples
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and CD34.
SCNP Nomenclature and Metrics
In SCNP terminology a ‘‘signaling node’’ is used to refer to a
proteomic readout in the presence or absence of a specific
modulator. For example, the response to FLT3L treatment can be
measured using p-Stat5 as a readout. That signaling node is
designated ‘‘FLT3L R p-Stat5’’. Several metrics (normalized
assay readouts defined below and summarized in Figure 1) are
applied to interpret the functionality and biology of each signaling
node and are referenced following the node e.g. ‘‘FLT3LRp-Stat5
| Fold’’, ‘‘G-CSFRp-Stat5 | Total’’ or ‘‘p-Stat5 | Basal’’. These
metrics were developed to measure distinct functional aspects of
signaling proteins (Figure 1). To measure basal levels of signaling
in the resting, unmodulated state, the ‘‘Basal’’ metric was applied.
With modulation, the ‘‘Fold’’ metric identifies the inducibility or
responsiveness of a protein or pathway. The ‘‘Total’’ metric was
developed to assess the magnitude of total activated protein. It
incorporates both basal and induced pathway activation and is
more relevant in measuring pathways regulated by activity
thresholds. For surface markers, the Relative Protein Expression
(‘‘Rel. Expression’’) was used to measure the amount of surface
expression and the Percent Positive (‘‘PercentPos’’) was used to
quantify the frequency of cells positive for a surface marker,
relative to a control antibody. For Apoptosis conditions, the
percentage of cells in a two-dimensional flow plot quadrant
‘‘Quad’’ region e.g. the p-Chk2-,c-PARP+ quadrant defined by
low levels of p-Chk2 (measuring DNA damage response) and high
levels of caspase product cleaved-PARP were used to quantify
levels of cellular apoptosis in response to cytotoxic drugs.
Signaling responses for the node | metric PMAR p-Erk | Fold
(a pharmacological stimulus which bypasses the need for specific
surface receptors but still requires intracellular signal transduction)
were $0.40 for 33/34 samples in study one and 82/83 samples in
study two suggesting that the majority of samples were capable of
induced signaling responses.
Association between Signaling Nodes and FLT 3
Receptor Mutational Status – Univariate Analysis
All signaling nodes (Table S1) were independently tested for
their ability to classify patients based on their FLT3 receptor
mutational status (ITD or WT). Due to the small sample size and
non-normal distribution of some node/metrics, based on visual
inspection, both Student t-test and Wilcoxon p values were
computed. The area under the curve of the receiver operator
characteristic (AUCROC) [66–68] was computed to assess
classification accuracy of each node.
Correlations between Node/Metrics
Pearson correlation coefficients were computed between all
pairs of signaling nodes.
Association between Multiple Node/Metric and FLT3
Mutational Status – Multivariate Analysis
All possible pairs of the 80 node/metrics that were considered to
be stratifying via univariate analysis (AUC $0.7 or lowest p#0.05)
were evaluated for their ability to complement each other in
stratifying the FLT3 receptor mutational status. A logistic
regression model of the form
FLT3{ITD Status~a1za2  N1za3  N2
was built for each pair. a1 is the intercept for the model. N1 and N2
are the first and the second node/metrics respectively. The
coefficients a1 and a2 are tested for their significance for being
different from zero. Models in which both the nodes/metrics have
a significant p-value (slope = 0) are considered to be the nodes/
metrics combinations with improved predictive value. All pairs for
which the p-values were significant and the AUC for the model
was greater than 0.90 (the highest AUC for an individual node/
metric) were examined further.
Outlier Analysis by Signaling
For each node /metric that stratified FLT3-ITD from FLT3-
WT the list of outlier donors that are outside of 1.5 times the inter-
quartile range was created. In particular, the outliers from one
class (e.g. FLT-3-ITD) that are more similar to the donors in the
second class (e.g. FLT-3- WT) were identified and summarized in
a table together with their clinical characteristics.
Supporting Information
Figure S1 Survival curves. Survival curves in weeks for FLT3-
ITD samples (dotted line) and FLT3-WT samples (solid line) are
shown for A) Study 1 and B) Study 2.
Found at: doi:10.1371/journal.pone.0013543.s001 (0.59 MB TIF)
Figure S2 Assessment of false discovery rate. Expected versus
actual numbers of stratifying node/metrics at specific P-value
thresholds (for FLT3-WT and FLT3-ITD stratification) demon-
strate significantly higher numbers of actual stratifying node/
metrics observed in A) Study 1 and B) Study 2 than would be
found by chance alone.
Found at: doi:10.1371/journal.pone.0013543.s002 (0.77 MB TIF)
Figure S3 Basal PI3K and Jak/Stat activity in FLT3-WT and
FLT3-ITD samples. A) Box and whisker plots for basal levels of p-
S6, p-Erk, p-Akt in Study 1 (left panels) and Study 2 (right panels).
Similar basal levels of p-S6, p-Erk, p-Akt were observed in FLT3-
WT and FLT3-ITD samples. B) Box and whisker plots for basal
levels of p-Stat1, p-Stat3 and p-Stat5 in Study 1 (left panels) and
Study 2 (right panels). Higher levels of basal p-Stat1, p-Stat3, p-
Stat5 were observed in FLT3-ITD samples in Study 1 but not
Study 2. Note: Absolute values are not comparable between
studies due to different experimental configurations.
Found at: doi:10.1371/journal.pone.0013543.s003 (3.30 MB TIF)
Figure S4 Additional FLT3L induced signaling readouts. Box
and whisker plots for FLT3L induced p-Akt, p-Erk, and p-CREB
in Study 1 (left panels) and p-Akt, and p-Erk in Study 2 (right
panels). FLT3-ITD samples demonstrated generally lower FLT3L
induced p-Akt, p-Erk, and p-CREB compared to FLT3-WT
samples. Note: Absolute values are not comparable between
studies due to different experimental configurations.
Found at: doi:10.1371/journal.pone.0013543.s004 (1.73 MB TIF)
Figure S5 IL-27 and FLT3L signaling in FLT3-ITD and NPM1
molecular subgroups. A) Shown are box and whisker plots of
FLT3L induced p-S6, p-Erk and p-Akt (Panel A) and for IL-27
induced p-Stat responses (Panel B) for Study 1 (upper rows) and
Study 2 (lower rows) in molecular subgroups. FLT3 NPM1
molecular subgroups are coded by shape: FLT3-ITD, NPM1
mutated (circles); FLT3-ITD, NPM1-WT (squares); FLT3 WT,
NPM1 mutated (+ signs); FLT3 WT, NPM1 WT (X signs). For
both IL-27 induced Jak/Stat signaling and FLT3L induced PI3K
and Raf signaling, the most variability and largest range of
response were observed within FLT3-WT NPM1-WT AML
samples. In contrast, more homogenous signaling responses were
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ITD or NPM1 mutated).
Found at: doi:10.1371/journal.pone.0013543.s005 (0.26 MB TIF)
Figure S6 Apoptosis nodes predict CR duration within FLT3-
WT samples. A) Descriptive statistics for the ability of apoptosis
nodes (Ara/Dauno R c-PARP| Fold, Etoposide R c-PARP| Fold)
to stratify patients with CR duration of ,2 years and patients with
CR duration .2 years. P values, AUCROC statistics, mean value of
apoptosis responses (Mean) and number (N) of patients per group
are shown. B) Examples of apoptosis responses from FLT3-WT
samples with CR Duration ,2 years (left) and CR duration .2
years (right) are shown by overlaid histograms of cleaved PARP
from unmodulated/basal (gray) and Ara/Dauno treated (black)
conditions. Within FLT3-WT AML samples, apoptosis nodes Ara-
C/Daunorubicin R c-PARP and Etoposide R c-PARP demon-
strate higher induced apoptotic response in Complete Continuous
Remission (CCR) patients with CR duration .2 years than in CR
patients whose remission was ,2 years.
Found at: doi:10.1371/journal.pone.0013543.s006 (0.11 MB TIF)
Figure S7 Example of gating analysis to define leukemic blast
population. Flow cytometry plots and sequential gating scheme. A)
Flow cytometry dot plot indicating how non-cellular debris were
excluded using a FSC and SSC gate. B) Flow cytometry dot plot
indicating how non-viable cells were excluded with a SSC and
Aqua viability dye gate. This gating scheme ensured that only
from live cells were analyzed for signaling responses. C) Flow
cytometry dot plot indicating how lymphocytes were excluded and
myeloid leukemic blasts included using additional surface markers
(i.e., CD45, CD33). Note: In the subset of AML samples with
phenotypically mature blasts (CD34- CD11b++, CD33++) a small
number of mature monocytes may also be included in this analysis,
however, due to the abnormally high percentage of myeloid cells
in these patients, the population analyzed likely contains
predominately leukemic cells. Unfortunately, the side scatter
properties of mature monocytes which clearly distinguish these
cells from leukemic blasts are compromised by the fixation and
permeabilization techniques used.
Found at: doi:10.1371/journal.pone.0013543.s007 (0.92 MB TIF)
Table S1 List of nodes tested.
Found at: doi:10.1371/journal.pone.0013543.s008 (0.07 MB
PDF)
Table S2 Variance in signaling between healthy BMMb and
FLT3 NPM1 molecular subgroups.
Found at: doi:10.1371/journal.pone.0013543.s009 (0.03 MB
PDF)
Table S3 Top-ranking nodes stratifying ITD from WT in Study
1 (univariate analysis).
Found at: doi:10.1371/journal.pone.0013543.s010 (0.09 MB
PDF)
Table S4 Top ranking nodes stratifying ITD from WT in Study
2 (univariate analysis).
Found at: doi:10.1371/journal.pone.0013543.s011 (0.08 MB
PDF)
Table S5 Pearson correlations between stratifying nodes for
FLT3-ITD vs. FLT3-WT in Study 1.
Found at: doi:10.1371/journal.pone.0013543.s012 (0.21 MB
PDF)
Table S6 Combinations/pairs of nodes from linear regression
analysis improve stratification of FLT3-ITD and WT samples in
Study 1.
Found at: doi:10.1371/journal.pone.0013543.s013 (0.08 MB
PDF)
Table S7 Clinical characteristics of cytogenetically normal (CN)
AML patient samples.
Found at: doi:10.1371/journal.pone.0013543.s014 (0.07 MB
PDF)
Table S8 Clinical characteristics of FLT3-WT vs. FLT3-ITD
signaling outliers (Study 2).
Found at: doi:10.1371/journal.pone.0013543.s015 (0.06 MB
PDF)
Table S9 List of modulators, reagents and technical conditions.
Found at: doi:10.1371/journal.pone.0013543.s016 (0.08 MB
PDF)
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